In accordance, ICC with anti-C/EBPa and anti-Pparr antibodies showed no discernable differences between the β-catenin–p53–Tm+ and β-catenin–Tm+ MPCs (Fig. 5D). The gene discussed is CEBPA; the disease is intrahepatic cholangiocarcinoma.